TD Cowen raised the firm’s price target on Travere Therapeutics (TVTX) to $30 from $24 and keeps a Buy rating on the shares. The firm said Q4 Filspari results were in line with the preannouncement with impressive 40% quarter-over-quarter sales growth and a 37% quarter-over quarter increase in PSFs. Filspari growth in IgAN should continue in 2025 as there are multiple tailwinds and the FSGS sNDA submission should occur by the end of Q1 setting up a potential approval by year-end.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics Posts Strong 2024 Financial Results
- Strong Growth Potential and Strategic Advancements Drive Buy Rating for Travere Therapeutics
- Closing Bell Movers: Booking gains 3%, Akamai down 8% on earnings
- Is TVTX a Buy, Before Earnings?
- Travere Therapeutics price target raised to $47 from $45 at Guggenheim